BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, F...

Read more
Subscribe to Directory
Write an Article

Highlight

Ardian crea el grupo MonBake tras cerrar...

by Ardian

Ardian, uno de los mayores fondos de inversión de Europa, cerró ayer...

Más de 400 empresas inscritas en el nue...

by Lanzadera

Las empresas seleccionadas podrán recibir ayudas que van desde los 4....

Photos Stream